Adasuve is a drug owned by Alexza Pharmaceuticals Inc. It is protected by 18 US drug patents filed from 2013 to 2017. Out of these, 1 drug patents are active and 17 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 23, 2026. Details of Adasuve's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9687487 | Aerosol forming device for use in inhalation therapy |
Oct, 2021
(3 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8387612 | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(1 year, 10 months from now) | Active |
| US7537009 | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(a month ago) |
Expired
|
| US7458374 | Method and apparatus for vaporizing a compound |
Aug, 2024
(4 months ago) |
Expired
|
| US8991387 | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(7 months ago) |
Expired
|
| US9370629 | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(7 months ago) |
Expired
|
| US6716416 | Delivery of antipsychotics through an inhalation route |
May, 2022
(2 years ago) |
Expired
|
| US7052679 | Delivery of antipsychotics through an inhalation route |
Mar, 2022
(2 years ago) |
Expired
|
| US9440034 | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) |
Expired
|
| US9439907 | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) |
Expired
|
| US8173107 | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) |
Expired
|
| US8235037 | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) |
Expired
|
| US7090830 | Drug condensation aerosols and kits |
Oct, 2021
(3 years ago) |
Expired
|
| US7585493 | Thin-film drug delivery article and method of use |
Oct, 2021
(3 years ago) |
Expired
|
| US7078020 | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) |
Expired
|
| US7601337 | Delivery of antipsychotics through an inhalation route |
Oct, 2021
(3 years ago) |
Expired
|
| US8074644 | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) |
Expired
|
| US8955512 | Method of forming an aerosol for inhalation delivery |
Oct, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adasuve's patents.
Latest Legal Activities on Adasuve's Patents
Given below is the list of recent legal activities going on the following patents of Adasuve.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 10 Jun, 2024 | US8173107 |
| Maintenance Fee Reminder Mailed Critical | 06 May, 2024 | US9440034 |
| Maintenance Fee Reminder Mailed Critical | 06 May, 2024 | US9439907 |
| Maintenance Fee Reminder Mailed Critical | 25 Mar, 2024 | US8235037 |
| Expire Patent Critical | 15 Jan, 2024 | US8074644 |
| Maintenance Fee Reminder Mailed Critical | 25 Dec, 2023 | US8173107 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Dec, 2023 | US9370629 |
| Maintenance Fee Reminder Mailed Critical | 31 Jul, 2023 | US8074644 |
| Expire Patent Critical | 27 Mar, 2023 | US8955512 |
| Maintenance Fee Reminder Mailed Critical | 10 Oct, 2022 | US8955512 |
FDA has granted several exclusivities to Adasuve. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Adasuve, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Adasuve.
Exclusivity Information
Adasuve holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Adasuve's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
US patents provide insights into the exclusivity only within the United States, but Adasuve is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adasuve's family patents as well as insights into ongoing legal events on those patents.
Adasuve's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adasuve's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 23, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adasuve Generics:
There are no approved generic versions for Adasuve as of now.
About Adasuve
Adasuve is a drug owned by Alexza Pharmaceuticals Inc. It is used for managing acute agitation in adults with schizophrenia or bipolar I disorder. Adasuve uses Loxapine as an active ingredient. Adasuve was launched by Alexza Pharms in 2012.
Approval Date:
Adasuve was approved by FDA for market use on 21 December, 2012.
Active Ingredient:
Adasuve uses Loxapine as the active ingredient. Check out other Drugs and Companies using Loxapine ingredient
Treatment:
Adasuve is used for managing acute agitation in adults with schizophrenia or bipolar I disorder.
Dosage:
Adasuve is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | POWDER | Prescription | INHALATION |